The prognostic value of elevated vascular endothelial growth factor in patients with osteosarcoma: a meta-analysis and systemic review

Jian, Qu; Wang, Mei; He, Hailong; Tang, Yu; Ye, Xiaojian

doi:10.1007/s00432-012-1149-7

Cited by 28 publications

(22 citation statements)

References 22 publications

(43 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As one of the most common primary malignant bone tumors in the world, osteosarcoma is a highly malignant mesenchymal-based tumor that mainly presents in children and teenagers [1, 2]. The annual morbidity of osteosarcoma is approximately 5 million cases worldwide [3] with prevalence towards males at a ratio of 1.5 : 1.…”

Section: Introductionmentioning

confidence: 99%

Artesunate Decreases β-Catenin Expression, Cell Proliferation and Apoptosis Resistance in the MG-63 Human Osteosarcoma Cell Line

Chen

Gong

et al. 2017

Cell Physiol Biochem

View full text Add to dashboard Cite

Background: This study aims to determine the effects of artesunate on proliferation, apoptosis and β-catenin expression in the human osteosarcoma cell line MG-63. Methods: MG-63 cells in the logarithmic growth phase were collected and cultured with different concentrations of artesunate (12.5 µg/mL, 25 µg/mL and 50 µg/mL) for 24 h, 48 h and 72 h. The total number of MG-63 cells and the morphological changes were observed under an inverted microscope. The MTT assay was adopted to test the inhibition rate (IR) of cell growth. The apoptosis rate was detected using annexin V/propidium iodide (PI) staining. Cell cycle distribution was identified by flow cytometry (FCM), and the expression levels of β-catenin, cyclins and cyclin dependent kinases (CDKs) were measured using Western blotting. Results: The results of the MTT assay indicated that artesunate could remarkably inhibit MG-63 cell proliferation compared with the rates in the untreated control group (0 µg/mL artesunate), and the inhibitory effect was dose-dependent. The apoptosis rate of MG-63 cells was elevated as the concentration of artesunate increased, and all the rates were significantly higher than that in the control group. Additionally, as the artesunate concentration increased, the proportion of MG-63 cells in G0/G1 phase gradually declined whereas that of cells in the G2/M and S phases increased. Western blotting confirmed that a higher concentration of artesunate reduced the expression levels of β-catenin, cyclin A, cyclin D1 and CDK1 and increased the expression levels of cyclin B1; however, artesunate had no impact on CDK2 expression in MG-63 cells. Conclusion: These results demonstrated that artesunate can inhibit β-catenin expression and cell proliferation as well as promote cell apoptosis in MG-63 cells, which indicates that artesunate may serve as a promising drug in the clinical treatment of osteosarcoma.

show abstract

Section: Introductionmentioning

confidence: 99%

Artesunate Decreases β-Catenin Expression, Cell Proliferation and Apoptosis Resistance in the MG-63 Human Osteosarcoma Cell Line

Chen

Gong

et al. 2017

Cell Physiol Biochem

View full text Add to dashboard Cite

show abstract

“…Inducing angiogenesis is one of the hallmarks of cancer (Hanahan et al, 2011) , and VEGF, as one of the most important regulators in tumor angiogenesis (Ferrara, 2004), has been thought to be valuable of predicting poor outcome of survival in several cancers, such as lung cancer (Zhan et al, 2009), hepatocellular carcinoma (Schoenleber et al, 2009), gastric cancer (Chen et al, 2011), ovarian cancer (Yu et al, 2012), and osteosarcoma (Qu et al, 2012). However, the prognostic value of VEGF in bladder cancer was undetermined.…”

Section: Discussionmentioning

confidence: 99%

Prognostic Value of Tissue Vascular Endothelial Growth Factor Expression in Bladder Cancer: a Meta-analysis

Huang¹,

Qi²,

He³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…The results indicated that VEGF (Qu et al, 2012) and HER-2 (Li and Geng, 2010) were not significantly associated with prognosis in human osteosarcoma, whereas TP53 (Pakos et al, 2004) and P-glycoprotein (Pakos and Ioannidis, 2003) were significantly associated with prognosis in patients with osteosarcoma. However, besides our study, these meta-analyses consider Ezrin positivity was associated with a lower 2-year survival rate.…”

Section: Meta-analysis On Ezrin Gene Associations With Response To Chmentioning

confidence: 75%

“…Recently, many meta-analyses have been performed to investigate the association between many genes (VEGF (Qu et al, 2012), HER-2 (Li and Geng, 2010), TP53 (Pakos et al, 2004), P-glycoprotein (Pakos and Ioannidis, 2003) et al) and prognosis in patients with osteosarcoma. The results indicated that VEGF (Qu et al, 2012) and HER-2 (Li and Geng, 2010) were not significantly associated with prognosis in human osteosarcoma, whereas TP53 (Pakos et al, 2004) and P-glycoprotein (Pakos and Ioannidis, 2003) were significantly associated with prognosis in patients with osteosarcoma.…”

Section: Meta-analysis On Ezrin Gene Associations With Response To Chmentioning

confidence: 99%

Meta-analysis of Associations of the Ezrin Gene with Human Osteosarcoma Response to Chemotherapy and Prognosis

Wang

He²,

Zhao³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Various studies examining the relationship between Ezrin overexpression and response to chemotherapy and clinical outcome in patients with osteosarcoma have yielded inconclusive results. We accordingly conducted a meta-analysis of 7 studies (n = 318 patients) that evaluated the correlation between Ezrin and histologic response to chemotherapy and clinical prognosis (death). Data were synthesized in receiver operating characteristic curves and with fixed-effects and random-effects likelihood ratios and risk ratios. Quantitative synthesis showed that Ezrin is not a prognostic factor for the response to chemotherapy. The positive likelihood ratio was 0.538 (95% confidence interval [95% CI], 0.296-0.979; random-effects calculation), and the negative likelihood ratio was 2.151 (95% CI, 0.905-5.114; random-effects calculations). There was some between-study heterogeneity, but no study showed strong discriminating ability. Conversely, Ezrin positive status tended to be associated with a lower 2-year survival (risk ratio, 2.45; 95% CI, 1.26-4.76; random-effects calculation) with some between-study heterogeneity that disappeared when only studies that employed immunohistochemistry were considered (risk ratio, 2.97; 95% CI, 2.01-4.40; fixed-effects calculation). To conclude, Ezrin is not associated with the histologic response to chemotherapy in patients with osteosarcoma, whereas Ezrin positivity was associated with a lower 2-year survival rate regarding risk of death at 2 years. Expression change of Ezrin is an independent prognostic factor in patients with osteosarcoma.

show abstract

The prognostic value of elevated vascular endothelial growth factor in patients with osteosarcoma: a meta-analysis and systemic review

Cited by 28 publications

References 22 publications

Artesunate Decreases β-Catenin Expression, Cell Proliferation and Apoptosis Resistance in the MG-63 Human Osteosarcoma Cell Line

Artesunate Decreases β-Catenin Expression, Cell Proliferation and Apoptosis Resistance in the MG-63 Human Osteosarcoma Cell Line

Prognostic Value of Tissue Vascular Endothelial Growth Factor Expression in Bladder Cancer: a Meta-analysis

Meta-analysis of Associations of the Ezrin Gene with Human Osteosarcoma Response to Chemotherapy and Prognosis

Contact Info

Product

Resources

About